Humira Buyers Get Backing Against AbbVie's 'Patent Thicket'

Law360 (October 13, 2020, 9:09 PM EDT) -- Consumer advocates, academics and a drug store industry group all have urged the Seventh Circuit to revive a lawsuit claiming AbbVie built an anti-competitive "patent thicket" around its blockbuster immunosuppressant Humira to keep cheaper biosimilars from coming to the market.

An Illinois federal judge failed to consider the cumulative impacts of AbbVie's bid for more patent protection and the settlements it cut with rival companies who were seeking to market their own versions of the treatment, according to amicus briefs filed Friday from the National Association of Chain Drug Stores Inc., Consumer Action and U.S. Public Interest Research Group, Open Markets...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!